Study questions impact of hemoglobin variations on mortality in dialysis patients

For patients with dialysis-related anemia, the risk of death is increased when hemoglobin levels remain persistently low over a period several months—not necessarily when they fluctuate over time, according to a study in the January Clinical Journal of the American Society of Nephrology.

"Our results show that the effect of hemoglobin variability on mortality, beyond the absolute level of hemoglobin, may not confer much additional risk, after adjusting for other illnesses and hospitalizations," comments David T. Gilbertson, Ph.D., of the Minneapolis Medical Research Foundation, Minneapolis, Minn.

Dr. Gilbertson and colleagues used data on nearly 160,000 dialysis patients to analyze the effects of variations in hemoglobin level on the risk of death. Patterns of hemoglobin variability during the first six months of 2004 were analyzed and compared with mortality rates over the subsequent six months.

Hemoglobin is the oxygen-carrying compound in the blood. Anemia, or low hemoglobin levels, is one of the most frequent complications of kidney failure and is associated with an increased risk of death in dialysis patients. Treatment including erythropoietin and intravenous iron has been a major advance in the management of kidney failure-related anemia, yet low blood counts and variation in hemoglobin levels continue to be a problem for many dialysis patients.

In the study, patients who developed low hemoglobin levels during the monitoring period were at increased risk of death. This was true both for patients with temporary reductions in hemoglobin and those whose hemoglobin level was persistently low. This risk was considerably greater than any risk associated with fluctuations in hemoglobin levels.

On further analysis, the key risk factor seemed to be the amount of time spent with a low hemoglobin level—not the hemoglobin variations themselves. Patients who spent three months or longer with low hemoglobin levels had the highest mortality rates.

"A number of research groups have shown that variability of hemoglobin levels is very common in patients receiving dialysis for end-stage renal disease," says Dr. Gilbertson. "Low hemoglobin levels, which are an indication of anemia, have been shown to be associated with poor outcomes. It is relatively unknown whether fluctuations in hemoglobin levels add additional risk." If so, then more intensive treatment might be needed to keep hemoglobin levels within a relatively narrow range.

"Our results suggest that fluctuations in hemoglobin levels probably do not add much to the mortality risk for patients with dialysis-related anemia," Dr. Gilbertson concludes. "Low hemoglobin levels show significantly greater associations with increased risk of death than fluctuations in hemoglobin levels." More research will be needed to evaluate the causes of variations in hemoglobin levels, including what proportion of the variability is under the control of doctors and dialysis centers.

Source: American Society of Nephrology

Related stories:

Researchers find gene linked to severe diabetic eye and kidney diseases
Researchers at the John A. Moran Eye Center at the University of Utah and collaborative institutions have identified a gene called erythropoietin (EPO) that contributes to increased risk of severe diabetic eye and kidney diseases, called retinopathy and nephropathy.
Drug for anemic cancer patients raises risk of death
Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called erythropoiesis-stimulating agents (ESAs), actually raise patients' risk of death, possibly by stimulating the growth of cancer cells.
Standard test for blood sugar control not accurate in diabetic dialysis patients
The standard test for measuring blood sugar control in people with diabetes is not accurate in those on kidney hemodialysis, according to new research at Wake Forest University Baptist Medical Center.
Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.
Gene variant linked to moderated symptoms of beta-thalassemia
Beta-thalassemia is a serious, potentially life-threatening disease that affects red blood cells, cells that carry oxygen via hemoglobin throughout the body. As part of the SardiNIA Study of Aging, supported by the National Institute on Aging (NIA), a component of the National Institutes of Health, scientists have found a genetic variant in the BCL11A gene that can explain why some people with beta-thalassemia seem to be protected from most dangerous symptoms. The findings appear this week in Proceedings of the National Academy of Sciences.
Testosterone supplementation for older men appears to have limited benefit
Older men with low testosterone levels who received testosterone supplementation increased lean body mass and decreased body fat, but were no stronger and had no improvement in mobility or cognition compared with men who did not use the supplement, according to a study in the January 2 issue of JAMA.
Genetic variation may reduce Alzheimer's risk
Adults with a genetic variation enabling them to express higher levels of fetal hemoglobin may have a reduced risk of Alzheimer's disease, researchers say.
Study Links Form of 'Bad' Cholesterol with Heart Attack Risk
A blood component called glycated LDL -- a form of low-density lipoprotein, the "bad" cholesterol, with a sugar molecule attached -- is known to be higher in diabetics than non-diabetics, and extensive research has shown that diabetics are at increased risk of a heart attack.

News discussion:

Medicine & Health news